🏷

Classifications

Harrison's Chapter

🔗

Mappings

MONDO

MONDO:0041996 thallium poisoning

Primary MONDO disease identifier for thallium poisoning.

📘

Definitions

2

Clinical toxic exposure syndrome definition for thallium poisoning

Thallium poisoning is a multisystem toxic syndrome caused by exposure to thallium salts, with especially characteristic painful peripheral neuropathy and alopecia superimposed on broader gastrointestinal, cutaneous, neuropsychiatric, and visceral toxicity.

CASE_DEFINITION Disease-level clinical framing across acute and delayed presentations

Show evidence (2 references)

PMID:14579545 SUPPORT Human Clinical

"The major manifestations of toxicity consist of a rapidly progressive, ascending, extremely painful sensory neuropathy and alopecia."

Supports the defining clinical syndrome of thallium poisoning as a toxic disorder centered on painful neuropathy and alopecia.

PMID:6338655 SUPPORT Human Clinical

"The symptomatology of its toxicity is usually nonspecific due to the multi-organ involvement."

Supports framing the disorder as a multisystem toxicity rather than an isolated neurologic or dermatologic disease.

Practical diagnostic definition for suspected thallium poisoning

Practical diagnosis relies on recognizing the combination of gastrointestinal, neurologic, and cutaneous findings and confirming exposure with blood or urine thallium measurement.

DIAGNOSTIC_CRITERIA Clinical recognition and laboratory confirmation in suspected poisoning

Show evidence (2 references)

PMID:33438838 SUPPORT Human Clinical

"The correct diagnosis was confirmed by blood and urine thallium assays."

Supports laboratory confirmation of suspected thallium poisoning using blood and urine assays.

PMID:33438838 SUPPORT Human Clinical

"Thallium intoxication may have been initially identified if neurologic symptoms had occurred concurrently with gastrointestinal and cutaneous symptoms."

Supports the practical diagnostic pattern of concurrent neurologic, gastrointestinal, and cutaneous manifestations.

◆

Subtypes

2

Acute Thallium Poisoning

Acute thallium poisoning follows a higher-dose ingestion or other intense exposure and presents first with gastrointestinal and neuropsychiatric symptoms, with severe cases progressing to convulsions, coma, pulmonary injury, and multi-organ failure.

Show evidence (2 references)

PMID:6338655 SUPPORT Human Clinical

"The initial symptoms of thallium poisoning may include fever, gastrointestinal problems, delirium, convulsions and coma."

Supports an acute presentation marked by early gastrointestinal and neurologic toxicity.

PMID:40884943 SUPPORT Human Clinical

"The cause of death in this case was thus determined to be ARDS caused by acute Tl poisoning."

Supports that severe acute poisoning can progress to fatal pulmonary injury and multi-organ failure.

Delayed neurocutaneous thallium poisoning

After the initial exposure phase, patients commonly evolve into a delayed neurocutaneous syndrome with painful polyneuropathy, alopecia, skin and nail changes, and persistent neurologic sequelae.

Show evidence (1 reference)

PMID:6338655 SUPPORT Human Clinical

"Symptoms may appear rapidly, but more commonly the acute toxicity subsides to be replaced by a gradual development of mild gastrointestinal disturbances, polyneuritis, encephalopathy, tachycardia, skin eruptions, stomatitis, atrophic changes of the skin, nail changes (Mee's lines), and skin..."

Supports a delayed subacute phase dominated by progressive neurocutaneous manifestations after the earliest toxic presentation.

📚

References

10

PMID:6338655

Thallium poisoning: a review.

No top-level findings curated for this source.

PMID:14579545

Thallium toxicity and the role of Prussian blue in therapy.

No top-level findings curated for this source.

PMID:15252192

Soluble or insoluble prussian blue for radiocesium and thallium poisoning?

No top-level findings curated for this source.

PMID:33438838

Long-term misdiagnosis and neurologic outcomes of thallium poisoning: A case report and literature review.

No top-level findings curated for this source.

PMID:36537175

Thallium poisoning: a case report.

No top-level findings curated for this source.

PMID:28761262

Acute Alopecia: Evidence to Thallium Poisoning.

No top-level findings curated for this source.

PMID:31335706

Clinical characteristics and treatment of thallium poisoning in patients with delayed admission in China.

No top-level findings curated for this source.

PMID:11192464

Thallium poisoning during pregnancy: a case report and comprehensive literature review.

No top-level findings curated for this source.

PMID:40884943

Acute thallium poisoning: An autopsy case report and review of the literature.

No top-level findings curated for this source.

PMID:36403832

Integrated physiological, biochemical, and transcriptomic analysis of thallium toxicity in zebrafish (Danio rerio) larvae.

No top-level findings curated for this source.

⚙

Pathophysiology

10

Gastrointestinal absorption of thallium

Thallium salts are rapidly and nearly completely absorbed after exposure, with gastrointestinal ingestion being the most common route to clinically important poisoning.

transmembrane transport link

gastrointestinal tract link

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"Thallium salts are rapidly and nearly completely absorbed by virtually all routes, with gastrointestinal exposure being the most common route to produce toxicity."

Supports efficient thallium absorption and the importance of gastrointestinal exposure in establishing poisoning.

Systemic thallium distribution

After absorption, thallium rapidly distributes throughout the body, including nervous tissue, skin, and hair, enabling multisystem toxicity.

abnormal localization link ⚠ ABNORMAL

Show evidence (1 reference)

PMID:31335706 SUPPORT Human Clinical

"Thallium compounds can accumulate in the human body and be rapidly distributed throughout it, including in the skin and hair."

Directly supports widespread systemic distribution of thallium after absorption.

Potassium-mimetic cellular uptake

Thallium enters cells through potassium-handling pathways because its ionic charge and radius closely resemble potassium, disrupting intracellular ionic homeostasis.

response to potassium ion link potassium ion transport link ↕ DYSREGULATED intracellular monoatomic ion homeostasis link ↕ DYSREGULATED

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"Thallium enters cells by a unique process governed by its similarity in charge and ionic radius to potassium."

Directly supports potassium-mimetic cellular uptake as a core toxicokinetic mechanism.

Bioenergetic failure

Once inside cells, thallium impairs glycolysis, the Krebs cycle, and oxidative phosphorylation, creating a broad failure of energy production that contributes to multi-organ toxicity.

glycolytic process link ↓ DECREASED tricarboxylic acid cycle link ↓ DECREASED oxidative phosphorylation link ↓ DECREASED

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"thallium interferes with energy production at essential steps in glycolysis, the Krebs cycle, and oxidative phosphorylation."

Supports mitochondrial and cytosolic bioenergetic failure as a central mechanism of thallium toxicity.

Sodium-potassium ATPase inhibition

Thallium inhibits sodium-potassium ATPase, destabilizing membrane ion homeostasis and contributing to autonomic and central neurotoxicity.

sodium ion transport link ↓ DECREASED potassium ion transport link ↓ DECREASED

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"Additional effects include inhibition of sodium-potassium-adenosine triphosphatase"

Directly supports sodium-potassium ATPase inhibition as a distinct toxic mechanism in thallium poisoning.

Sulfhydryl-dependent molecular binding

Thallium binds sulfhydryl-containing molecules, perturbing protein function and contributing to downstream neurotoxicity.

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"binding to sulfhydryl groups."

Supports sulfhydryl binding as a distinct molecular lesion in thallium toxicity.

Peripheral nervous system injury

Thallium poisoning prominently injures the peripheral nervous system, producing a rapidly progressive, extremely painful ascending neuropathy and leaving persistent neurologic sequelae in some survivors.

peripheral nervous system neuron link

peripheral nervous system link

Show evidence (2 references)

PMID:14579545 SUPPORT Human Clinical

"The major manifestations of toxicity consist of a rapidly progressive, ascending, extremely painful sensory neuropathy and alopecia."

Supports painful ascending sensory neuropathy as the dominant neurologic expression of thallium toxicity.

PMID:33438838 SUPPORT Human Clinical

"Neurologic damage represented the main sequelae of thallium poisoning in our present case report."

Supports persistent neurologic injury as an important consequence of thallium neurotoxicity.

Autonomic and central neurotoxicity

In more severe poisoning, thallium toxicity extends beyond painful peripheral neuropathy into autonomic dysfunction and central nervous system injury.

autonomic neuron link central nervous system neuron link

autonomic nervous system link central nervous system link

Show evidence (2 references)

PMID:14579545 SUPPORT Human Clinical

"Many other findings such as an autonomic neuropathy, cranial nerve abnormalities, altered mental status, motor weakness, cardiac, hepatic, and renal effects are described, but are less specific."

Supports autonomic and central neurologic toxicity as a distinct branch of thallium poisoning.

PMID:31335706 SUPPORT Human Clinical

"Some patients with delayed admission had significant symptoms associated with central nervous system damage"

Supports central nervous system injury as a clinically important branch in delayed or severe poisoning.

Keratin affinity and appendage accumulation

Thallium has affinity for keratin-rich tissues and accumulates in hair and nails, establishing a distinct appendage-toxicity branch of poisoning.

keratinocyte link

skin of body link hair shaft link

Show evidence (1 reference)

PMID:28761262 SUPPORT Human Clinical

"Thallium does not have an internal anatomic reservoir, but has an affinity to keratin."

Supports keratin affinity and appendage accumulation as a distinct toxic branch.

Hair follicle toxicity

Thallium causes dystrophic anagen injury in hair follicles, which then manifests clinically as delayed diffuse alopecia.

hair follicle cell link

hair follicle development link ↓ DECREASED hair cycle link ⚠ ABNORMAL

hair follicle link hair shaft link

Show evidence (1 reference)

PMID:28761262 SUPPORT Human Clinical

"A trichogram revealed 95% of the hairs in dystrophic anagen status"

Supports direct hair follicle injury with dystrophic anagen changes in thallium poisoning.

✶

Histopathology

1

Diffuse alveolar damage and pulmonary edema in fatal acute poisoning

Fatal acute thallium poisoning can show severe pulmonary edema, pulmonary hemorrhage, and hyaline membrane formation, providing the histopathologic correlate of acute respiratory distress syndrome.

Show evidence (1 reference)

PMID:40884943 SUPPORT Human Clinical

"large amounts of pleural effusion, severe pulmonary edema, pulmonary hemorrhage, and hyaline membrane formation in the lung tissue suggested acute respiratory distress syndrome (ARDS)."

Supports diffuse acute lung injury with hyaline membrane formation as a histopathologic pattern in severe fatal thallium poisoning.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

5

Digestive 1

Constipation OCCASIONAL Constipation (HP:0002019)

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"Unlike exposure to most metal salts, gastrointestinal symptoms of thallium toxicity are relatively minor, and constipation is more characteristic than diarrhoea."

Supports constipation as a characteristic gastrointestinal phenotype in thallium toxicity.

Integument 1

Alopecia FREQUENT Alopecia (HP:0001596)

Show evidence (1 reference)

PMID:6338655 SUPPORT Human Clinical

"In humans the most characteristic sign of thallium toxicity is alopecia which usually appears in cases when death is delayed for 15-20 days."

Supports alopecia as the most characteristic delayed cutaneous sign of thallium poisoning.

Nervous System 2

Peripheral neuropathy FREQUENT Peripheral neuropathy (HP:0009830)

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"The major manifestations of toxicity consist of a rapidly progressive, ascending, extremely painful sensory neuropathy and alopecia."

Directly supports painful ascending peripheral neuropathy as a frequent hallmark phenotype.

Altered mental status OCCASIONAL Confusion (HP:0001289)

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"Many other findings such as an autonomic neuropathy, cranial nerve abnormalities, altered mental status, motor weakness, cardiac, hepatic, and renal effects are described, but are less specific."

Supports altered mental status as a recognized but less specific neurologic manifestation.

Constitutional 1

Abdominal pain FREQUENT Abdominal pain (HP:0002027)

Show evidence (1 reference)

PMID:33438838 SUPPORT Human Clinical

"We found that polyneuropathy (82%), alopecia (68%), and abdominal pain (51%) were the most frequent clinical manifestations"

Supports abdominal pain as one of the most frequent reported manifestations in thallium poisoning cases.

💊

Treatments

5

Exposure cessation and source removal

Action: chemical exposure avoidance MAXO:0000071

Management begins with immediate cessation of exposure and removal of the toxic source to prevent ongoing absorption.

Mechanism Target:

INHIBITS Gastrointestinal absorption of thallium — Source control prevents continued ingestion and limits additional thallium uptake.

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"Thallium salts are rapidly and nearly completely absorbed by virtually all routes, with gastrointestinal exposure being the most common route to produce toxicity."

Supports exposure cessation as an intervention that limits further gastrointestinal absorption of thallium.

Show evidence (1 reference)

PMID:36537175 SUPPORT Human Clinical

"An adequate clinical approach can facilitate early diagnosis."

Supports the clinical importance of early recognition, which is necessary for prompt removal from exposure and source control.

Prussian blue therapy

Action: antidote agent therapy MAXO:0000217

Prussian blue is the preferred antidotal therapy for acute thallium poisoning because it enhances gastrointestinal elimination and has the best available safety profile among proposed drug therapies.

Show evidence (2 references)

PMID:14579545 SUPPORT Human Clinical

"Prussian blue's safety profile is superior to that of other proposed therapies and it should be considered the drug of choice in acute thallium poisoning."

Directly supports Prussian blue as the preferred antidotal treatment in acute poisoning.

PMID:33438838 SUPPORT Human Clinical

"After Prussian blue treatment, thallium was undetectable in the blood by day 60."

Human case evidence supports effective thallium clearance during Prussian blue treatment.

Multiple-dose activated charcoal

Action: supportive care MAXO:0000950

Single- or multiple-dose activated charcoal can be used to reduce ongoing gastrointestinal absorption and interrupt enteroenteric or enterohepatic recycling.

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"The use of single- or multiple-dose activated charcoal is supported by in vitro binding experiments and some animal data"

Supports activated charcoal as an adjunctive decontamination strategy, though the evidence base is indirect.

Potassium supplementation

Action: pharmacotherapy MAXO:0000058

Potassium supplementation has historically been used to enhance thallium elimination and remains part of classic treatment regimens.

Show evidence (2 references)

PMID:6338655 SUPPORT Human Clinical

"The current therapy for thallium poisoning is the use of prussian blue and potassium chloride."

Supports potassium chloride as part of established treatment regimens for thallium poisoning.

PMID:6338655 SUPPORT Human Clinical

"Potassium therapy is probably the single most effective agent in the treatment of thallium poisoning."

Supports historical therapeutic use of potassium therapy to enhance elimination.

Extracorporeal elimination adjuncts

Action: hemodialysis MAXO:0000602

Hemoperfusion or hemodialysis may be used as adjunctive therapy in severe poisoning, especially when neurologic toxicity is advanced or ongoing elimination support is needed.

Show evidence (1 reference)

PMID:14579545 PARTIAL Human Clinical

"charcoal haemoperfusion may be a useful adjunct."

Supports extracorporeal elimination as an adjunctive rather than definitive therapy.

🌍

Environmental Factors

5

Industrial thallium salt exposure

Occupational or environmental exposure can occur through industrial thallium salts used in manufacturing processes.

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"Thallium salts have been used as medicinal agents, as key ingredients in a variety of manufacturing processes, and as a potent rodenticide."

Supports industrial thallium salts as an important exposure source.

Rodenticide exposure

Thallium-containing rodenticides have historically caused accidental and intentional poisonings where access remained possible.

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"Thallium salts have been used as medicinal agents, as key ingredients in a variety of manufacturing processes, and as a potent rodenticide."

Supports rodenticide use as a recognized exposure source for thallium poisoning.

Coal combustion and cement manufacturing exposure

Environmental thallium contamination can arise from industrial waste linked to coal combustion and cement manufacture.

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"environmental concerns are growing, as thallium is a waste product of coal combustion and the manufacturing of cement."

Supports coal combustion and cement manufacturing as environmental contamination sources.

Contaminated alternative medicine exposure

Contaminated traditional or alternative medicines can be an underrecognized source of acute thallium ingestion.

Show evidence (1 reference)

PMID:28761262 SUPPORT Human Clinical

"Here, we report a case of acute, nonintentional thallium poisoning due to thallium-contaminated alternative medicine"

Directly supports contaminated alternative medicine as a real-world exposure source.

Deliberate beverage contamination

Criminal poisoning by thallium-adulterated food or beverages remains an important forensic exposure context.

Show evidence (1 reference)

PMID:33438838 SUPPORT Human Clinical

"Following this investigation, a criminal suspect confessed to two instances of adulterating thallium sulfate in the patient's beverage."

Supports deliberate beverage adulteration as a documented exposure scenario.

🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Thallium Poisoning:

Arsenic Poisoning

Distinguishing Features

Thallium poisoning is more strongly associated with dramatic delayed alopecia
Thallium typically causes extremely painful ascending sensory neuropathy
Arsenic more often causes hyperpigmentation and palmoplantar keratoses in chronic exposure

Show evidence (1 reference)

PMID:14579545 SUPPORT Human Clinical

"The major manifestations of toxicity consist of a rapidly progressive, ascending, extremely painful sensory neuropathy and alopecia."

Supports the thallium-specific combination of painful ascending neuropathy and alopecia that helps distinguish it from arsenic poisoning.

Lead Poisoning

Distinguishing Features

Lead poisoning more often produces anemia, basophilic stippling, and chronic cognitive effects
Thallium poisoning is more strongly linked to alopecia and painful sensory neuropathy

Show evidence (1 reference)

PMID:6338655 SUPPORT Human Clinical

"In humans the most characteristic sign of thallium toxicity is alopecia which usually appears in cases when death is delayed for 15-20 days."

Supports alopecia as a strong distinguishing clue favoring thallium poisoning over lead poisoning.

Guillain-Barre Syndrome

Distinguishing Features

Thallium poisoning is suggested by gastrointestinal prodrome and delayed alopecia
Laboratory thallium assays confirm toxic exposure rather than postinfectious neuropathy

Show evidence (1 reference)

PMID:33438838 SUPPORT Human Clinical

"A 43-year-old man was initially misdiagnosed as gastroenteritis, diabetic peripheral neuropathy, and Guillain-Barré Syndrome (GBS) within 21 months."

Supports Guillain-Barre syndrome as a common clinical mimic in misdiagnosed thallium poisoning.

📊

Related Datasets

2

Transcriptomic alterations of thallium-exposed zebrafish embryos geo:GSE213589

Bulk RNA-seq toxicogenomic dataset profiling wild-type zebrafish embryos exposed to graded thallium concentrations during early development, useful for studying developmental and stress-response programs perturbed by thallium.

zebrafish BULK RNA SEQ n=10

Conditions: wild-type zebrafish embryos exposed to 0 ppb thallium wild-type zebrafish embryos exposed to 200 ppb thallium wild-type zebrafish embryos exposed to 800 ppb thallium

Exposures: exposure to thallium link

PMID:36403832

Dataset record: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE213589. Useful as a mechanistic toxicogenomic resource rather than a human clinical cohort.

Show evidence (1 reference)

GEO:GSE213589 SUPPORT Model Organism

"Thallium (Tl) is a trace metal element used in the electronics, semiconductor and electro-optical industries. With the development of high-tech industries, thallium severely pollutes the aquatic environment. The purpose of this study was to evaluate the cardiotoxicity and developmental toxicity..."

Supports this GEO series as a model-organism bulk RNA-seq resource directly profiling transcriptomic responses to graded thallium exposure.

Dissociation of mitochondrial and ribosomal biogenesis during thallium administration in rat kidney geo:GSE269635

Rat kidney microarray dataset profiling early transcriptomic responses after short-course thallium administration, useful for studying renal bioenergetic and stress-response pathways in thallium toxicity.

rat MICROARRAY n=3 ClariomS

Conditions: rat kidney control rat kidney after 2 days of thallium administration rat kidney after 5 days of thallium administration

Exposures: exposure to thallium link

Dataset record: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE269635. Useful as a mechanistic renal toxicogenomic resource rather than a human clinical cohort.

Show evidence (1 reference)

GEO:GSE269635 SUPPORT Model Organism

"We analyzed kidney from rats administered thallium (30 mg/kg, daily for 2 or 5 days) using the ClariomS platform."

Supports this GEO series as a rat kidney microarray resource for short-course experimental thallium toxicity.

📚

Literature Summaries

1

Asta ▸

Asta Literature Retrieval: Disease Pathophysiology Research Template Target Disease Disease Name: Thallium Poisoning MONDO ID: (if available) Ca...

Asta Scientific Corpus Retrieval 19 citations 2026-03-17T17:03:20.222923

Asta Literature Retrieval: Disease Pathophysiology Research Template Target Disease Disease Name: Thallium Poisoning MONDO ID: (if available) Ca...

This report is retrieval-only and is generated directly from Asta results.

Papers retrieved: 19
Snippets retrieved: 20

Relevant Papers

[1] D-Penicillamine Reveals the Amelioration of Seizure-Induced Neuronal Injury via Inhibiting Aqp11-Dependent Ferroptosis

Authors: Nan Yang, Kai Zhang, Qiwen Guan, Zhaoxin Wang, Kang-Ni Chen et al.
Year: 2022
Venue: Antioxidants
URL: https://www.semanticscholar.org/paper/9cbcd9c66c77d092ea31947f5258f8e2a8185b0a
DOI: 10.3390/antiox11081602
PMID: 36009321
PMCID: 9405105
Citations: 19
Summary: DPA can be repurposed to cure seizure disorders such as epilepsy, and the effects of DPA on ferroptosis process are dependent upon Aqp11, a gene coding previously reported channel protein responsible for transporting water and small solutes.
Evidence snippets:
Snippet 1 (score: 0.516) > The present work focused on the effects of DPA on seizure-induced neuronal injury and its potential molecular mechanism. The major findings of the study are shown as follows: > (1) DPA exerts the pronounced protection against seizure-induced neuronal impairment; > (2) ferroptosis is involved in the amelioration of DPA on the injured neurons post seizure; > (3) Aqp11 is identified to be a key molecular target for the inhibitory effect of DPA on neuronal ferroptosis in vitro and on seizure-induced neuronal damage in vivo (Figure 7). DPA is a first-line drug for treating Wilson's disease in clinical practice, and, also, has wide therapeutic applications in curing chronic active hepatitis, rheumatoid arthritis, systemic sclerosis, primary biliary cirrhosis and so on [41][42][43][44][45]. Previously, DPA has been demonstrated to mitigate the neurotoxicity caused by heavy metal thallium [46]. It has been reported that thallium poisoning can lead to neurological abnormalities that affect lower limb motor function [46,47]. Combinational treatment with DPA and Prussian blue significantly prevents the dysfunction of purkinje cells in the brain of thallium poisoned rats. These data indicate the alleviation of neurotoxicity after DPA treatment. In addition, DPA is a first-line drug for treating Wilson's disease in clinical practice, and, also, has wide therapeutic applications in curing chronic active hepatitis, rheumatoid arthritis, systemic sclerosis, primary biliary cirrhosis and so on [41][42][43][44][45]. Previously, DPA has been demonstrated to mitigate the neurotoxicity caused by heavy metal thallium [46]. It has been reported that thallium poisoning can lead to neurological abnormalities that affect lower limb motor function [46,47]. Combinational treatment with DPA and Prussian blue significantly prevents the dysfunction of purkinje cells in the brain of thallium poisoned rats. These data indicate the alleviation of neurotoxicity after DPA treatment.

[2] Comprehensive review on the pathogenesis of hypertriglyceridaemia-associated acute pancreatitis

Authors: Minhao Qiu, Xiaoying Zhou, M. Zippi, Hemant Goyal, Zarrin Basharat et al.
Year: 2023
Venue: Annals of Medicine
URL: https://www.semanticscholar.org/paper/45eb6adcd7600f6a642f6adcf51182e2de45ba30
DOI: 10.1080/07853890.2023.2265939
PMID: 37813108
PMCID: 10563627
Citations: 44
Influential citations: 1
Summary: An overview of triglyceride metabolism and the potential mechanisms that may contribute to developing or exacerbating hypertriglyceridaemia appears promising, with ongoing research focused on developing more specific and effective treatment strategies.
Evidence snippets:
Snippet 1 (score: 0.514) > HTAP is a complex disease with a multifactorial aetiology, and not fully understood pathophysiology.As our knowledge regarding the disease evolves, we are likely to develop more effective and targeted treatments, which can reduce the occurrence of more severe disease outcomes or prevent the disease altogether.Future research will need to focus on elucidating the underlying genetic and molecular mechanisms of the disease, as well as identifying specific pathways and targets that can be used to develop more effective treatments.This will require a multidisciplinary approach that combines genetics, molecular biology, and clinical research and will likely involve collaborations between basic and clinical scientists across multiple disciplines.Ultimately, developing more effective treatments for HTAP will require a deep understanding of the underlying pathophysiology of the disease, as well as the development of more targeted and personalized approaches to diagnosis and treatment.

[3] Emerging Trends in Pathophysiology: Insights from the 9th International Congress of the International Society for Pathophysiology (ISP 2023)

Authors: A. Kubyshkin, S. Bolevich, L. Churilov, V. Jakovljevic, E. Kovalenko et al.
Year: 2024
Venue: Pathophysiology
URL: https://www.semanticscholar.org/paper/3ab0c7d37d984c72ca8cba300cb8052c1326e61a
DOI: 10.3390/pathophysiology31010011
PMID: 38535621
PMCID: 10975917
Summary: The main trends and the most promising areas of research in current pathophysiology, including investigations of new pathogenic pathways, and the identification of cellular and molecular mechanisms, target molecules, genetic mechanisms, and new therapeutic strategies are described.
Evidence snippets:
Snippet 1 (score: 0.494) > This article provides a summary of the 9th International Congress of the International Society for Pathophysiology (ISP 2023) which took place in Belgrade, Serbia, from 4 to 6 July 2023. It describes the main trends and the most promising areas of research in current pathophysiology, including investigations of new pathogenic pathways, and the identification of cellular and molecular mechanisms, target molecules, genetic mechanisms, and new therapeutic strategies. The present article also highlights the research conducted by leading scientific teams and national pathophysiological societies from various countries that adds to our understanding of the pathogenesis of diseases and pathological processes.

[4] Of Mice and Men: Comparative Analysis of Neuro-Inflammatory Mechanisms in Human and Mouse Using Cause-and-Effect Models

Authors: A. Kodamullil, Anandhi Iyappan, Reagon Karki, S. Madan, E. Younesi et al.
Year: 2017
Venue: Journal of Alzheimer's Disease
URL: https://www.semanticscholar.org/paper/55820fd5fc6231bc4bf3c0330cb6cbfea9a4827c
DOI: 10.3233/JAD-170255
PMID: 28731442
PMCID: 5545904
Citations: 27
Summary: This paper investigates the failure of a neuroinflammation targeted drug in the late phases of clinical trials based on the comparative analyses between the two species and assesses to what extend a mouse can mimic the cellular and molecular interactions in humans at a mechanism level.
Evidence snippets:
Snippet 1 (score: 0.473) > Mouse models are extensively used in biomedical research mainly to understand the etiology of the disease. Complex diseases like AD may involve several simultaneous alterations in molecular and processual activities, including neuroinflammation, aggregation of A␤ peptides, or tau phosphorylation, which are likely to contribute to pathophysiology. In this paper, we have compared the mouse and human at molecular, cellular, and pathway levels to shed light on mechanistic differences with important implications for translation outcomes. Mechanistic modelling specific to species allows us to "embed" and "represent" similarities and differences in innate immunity which can lead to the development of "conflictious information detection engine". It is important to note that our analysis is purely based on the research and publication bias in mouse and human experiments as many mouse experiments are mainly focused on particular explorative areas, and experiments with human tissues are also concentrated on limited areas of disease mechanism. We found that mouse experiments often reveal new molecular interactions between different entities that are not observed or reported in human experiments. Differential analysis of mouse and human model for neuroinflammation shows that mouse and human differ at the molecular and cellular levels, but have more similarities at the pathway levels as numbers indicate. More explicitly, the underlying molecular patterns which lead to a particular bioprocess differ between the two species. This finding implies that although the two species share some similarities at the cellular or pathway level, the pattern of molecular interactions that form, govern, and regulate those pathways is substantially different between mouse and human. > It is notable that mouse models have provided significant insights into many disease areas like cancer; acute promyelocytic leukemia. However, recent drug failures in the area of neurodegeneration have put a question mark behind the extent to which mouse models have been used in preclinical drug discovery and to what extent transgenic mice mimic human brain pathophysiology mechanisms. Pathophysiology mechanisms are likely to act together and they seem to be organized in a temporal cascade of events that ultimately result in a severe disease phenotype. Experiments with single gene knock-out in mice can reveal only minor aspects of the disease perturbations and do not usually allow us to decipher the full complexity of the mechanisms underlying the disease.

[5] Integrative human and murine multi-omics: Highlighting shared biomarkers in the neuronal ceroid lipofuscinoses.

Authors: N. Gammaldi, F. Pezzini, E. Michelucci, N. Di Giorgi, A. Simonati et al.
Year: 2023
Venue: Neurobiology of disease
URL: https://www.semanticscholar.org/paper/2c50113653b538549410afe59f69ce70a4184a43
DOI: 10.1016/j.nbd.2023.106349
PMID: 37952681
Citations: 3
Summary: The results offer promising targets for potential new therapeutic strategies and reinforce the hypothesis of a connection between NCLs and other forms of dementia, particularly Alzheimer's disease.
Evidence snippets:
Snippet 1 (score: 0.472) > Recent methodological advances in multi-omics approaches have revolutionized research in rare diseases by balancing the low availability of samples and the poor information about pathophysiology with the generation of "big data", which has greatly enhanced our understanding of the molecular complexity underlying these diseases. Omics data can be integrated correlating them from different sources and technologies in order to identify affected disease pathways, biomarkers, as well as new pharmaceutical targets. > In the brain, common dysregulated pathways have been identified not only in NCLs, but also in almost every late-onset neurodegenerative and aging-related disorder, suggesting that targeting these common pathways may open up promising new therapeutic opportunities (Kline et al., 2020;Kodam et al., 2023;Schilder et al., 2022). > In this review, we explored the pathogenesis of NCL disease, evaluating human data in order to define common molecular networks underlying the top dysregulated processes. Moreover, by distinguishing between pre-symptomatic and symptomatic stages, we were able to evaluate disease progression in murine models from both a cell-specific and an anatomical point of view. We evaluated the cellular microenvironment, highlighting the main altered pathways and pinpointing processes implicated across species and in single forms. The results generated pave the way for identifying the different brain regions primarily affected by the disease.
Snippet 2 (score: 0.441) > Poor information on disease pathophysiology, and therefore on possible disease biomarkers, is a major obstacle to clinical trials in this field. Exploration of disease pathways likely shared by NCLs, such as oxidative phosphorylation, mitochondrial bioenergetics, autophagy (either macro-or mitophagy), and lysosomal clearance, may facilitate the process of biomarker discovery, making it possible to identify novel targets useful for monitoring disease status and progression, and accelerating trial readiness in patients. > The research field has recently benefited from the development of omics approaches allowing the generation of huge amounts of information even from small numbers of biological samples or cases. > Transcriptomics, in particular, has advanced considerably in recent years. Microarray platforms and high-throughput RNA sequencing have allowed high coverage of the human transcriptome, as well as that of the main animal models of the disease. > Proteomics, on the other hand, involving the use of mass spectrometry-based technologies, provides the most accurate insight into cellular physiology and disease biomarkers. Furthermore, new emerging disciplines are allowing the assessment of metabolomic and lipidomic analyses, increasing available information on the interplay between genes and the environment. > In this setting, one of the major challenges when seeking to determine the mechanisms underlying biological processes is sample complexity, given the possible presence of splice variants and/or posttranslational modification (Al-Amrani et al., 2021); another is the large volume of generated data, which require a validation process using different, non-omics approaches. > Although human samples, such as biological fluids, patient fibroblasts, and post-mortem tissues are, traditionally, the main samples used to investigate genetic, clinical, and biochemical factors, the increasing availability of in vitro and in vivo disease models has facilitated our understanding of disease pathophysiology and the screening of possible therapeutic targets.

[6] Novel Insights into the Molecular Mechanisms of Atherosclerosis

Authors: Armanda Wojtasińska, W. Frąk, Wiktoria Lisińska, Natalia Sapeda, Ewelina Młynarska et al.
Year: 2023
Venue: International Journal of Molecular Sciences
URL: https://www.semanticscholar.org/paper/fae6fbd9d1854df6a8d53eb43525ea8ec5af1cd7
DOI: 10.3390/ijms241713434
PMID: 37686238
PMCID: 10487483
Citations: 50
Summary: This review summarizes the available information on the pathophysiological implications of atherosclerosis, focusing on endothelium dysfunction, inflammatory factors, aging, and uric acid, vitamin D, and miRNA expression as recent evidence of interactions of the molecular and cellular elements.
Evidence snippets:
Snippet 1 (score: 0.471) > Atherosclerosis is one of the most fatal diseases in the world. The associated thickening of the arterial wall and its background and consequences make it a very composite disease entity with many mechanisms that lead to its creation. It is an active process, and scientists from various branches are engaged in research, including molecular biologists, cardiologists, and immunologists. This review summarizes the available information on the pathophysiological implications of atherosclerosis, focusing on endothelium dysfunction, inflammatory factors, aging, and uric acid, vitamin D, and miRNA expression as recent evidence of interactions of the molecular and cellular elements. Analyzing new discoveries for the underlying causes of this condition assists the general research to improve understanding of the mechanism of pathophysiology and thus prevention of cardiovascular diseases.

[7] Pathogenesis and Therapeutic Perspectives of Tubular Injury in Diabetic Kidney Disease: An Update

Authors: Jiamian Geng, Sijia Ma, Hui Tang, Chun-di Zhang
Year: 2025
Venue: Biomedicines
URL: https://www.semanticscholar.org/paper/889b3498a05a86b303b0fc3bd0f89915c65f39f0
DOI: 10.3390/biomedicines13061424
PMID: 40564143
PMCID: 12189843
Citations: 3
Summary: Advances in stem cell-based interventions and precision gene editing techniques have unveiled novel therapeutic paradigms for DKD, fundamentally expanding the treatment arsenal beyond conventional pharmacotherapy and highlighting promising therapeutic strategies for managing this condition.
Evidence snippets:
Snippet 1 (score: 0.468) > The adaptive mechanisms of cellular stress responses play a pivotal role in maintaining organismal homeostasis, conferring remarkable resilience against pathological processes and disease progression [65]. In the context of DKD, three primary forms of stress response mechanisms have been implicated in disease pathogenesis and clinical progression. These maladaptive responses manifest as oxidative stress-mediated cellular damage, ERS-induced protein homeostasis disruption, and mitochondrial dysfunction-related metabolic disturbances. Each pathway contributes distinctively to the complex pathophysiology of DKD through interconnected mechanisms of cellular injury and aberrant signaling cascades.

[8] Lactate metabolism and lactylation in kidney diseases: insights into mechanisms and therapeutic opportunities

Authors: Yuhua Cheng, Linjuan Guo
Year: 2025
Venue: Renal Failure
URL: https://www.semanticscholar.org/paper/6208b88884af543f7c97d2e70ed6b727dcfb4f58
DOI: 10.1080/0886022X.2025.2469746
PMID: 40012230
PMCID: 11869332
Citations: 9
Summary: A review examines the role of lactate esters, especially lactylation, in kidney diseases, with a focus on their regulatory mechanisms and potential as therapeutic targets.
Evidence snippets:
Snippet 1 (score: 0.463) > Lactate metabolism and its post-translational modifications, particularly lactylation, play critical roles in the pathophysiology of various kidney diseases, including AKI, DKD, and ccRCC (Figure 1). The kidney's ability to metabolize lactate is crucial for maintaining renal function under normal conditions. However, in pathological states, impaired lactate metabolism leads to its accumulation, exacerbating renal dysfunction and disease progression. For more details on lactate metabolism and kidney diseases, refer to previous reviews [2,3,25]. > Lactylation influences gene transcription, protein function, and cellular metabolism, contributing to inflammatory responses, mitochondrial dysfunction, and tumor progression. > Understanding the mechanisms of lactate metabolism and lactylation in kidney diseases opens new avenues for therapeutic interventions. Targeting these metabolic pathways could mitigate renal injury and improve patient outcomes. Future research should focus on elucidating the specific pathways and molecular targets affected by lactate and lactylation and developing inhibitors to modulate these processes. Clinical trials are necessary to validate the efficacy and safety of these therapies. Overall, the lactate-lactylation axis is a promising target for novel therapeutic strategies aimed at treating kidney diseases and improving renal health.

[9] Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical Research

Authors: G. Langley, C. Austin, A. Balapure, L. Birnbaum, J. Bucher et al.
Year: 2015
Venue: Environmental Health Perspectives
URL: https://www.semanticscholar.org/paper/b54081862ef66a83e34fe6a9c2586bc58b459c28
DOI: 10.1289/ehp.1510345
PMID: 26523530
PMCID: 4629751
Citations: 59
Summary: A new conceptual framework that repurposes the 21st-century transition underway in toxicology is suggested, conceived as resulting from integrated extrinsic and intrinsic causes, with research focused on modern human-specific models to understand disease pathways at multiple biological levels.
Evidence snippets:
Snippet 1 (score: 0.455) > In the context of disease research and drug discovery, our disease AOP concept would provide a unified framework for describing relevant pathophysiological pathways and networks across multiple biological levels and for encompassing extrinsic and intrinsic causes. Describing these pathways and networks, along with anchoring molecular initiating events with adverse outcomes, our AOP frame work would represent a significant advance over existing concepts, such as disease mechanisms that are often studied in isolation and biological pathways or networks (e.g., for cancers) that are invariably considered only at the molecular or cellular levels. > The disease AOP approach would better exploit advanced experimental and computational platforms for knowledge discovery, since the emergence of AOP networks will identify knowledge gaps and steer investigations accordingly. A commitment to build, curate, and disseminate a pathways framework within the biomedical research field would thus provide considerable impetus to base decisions on mechanistic understanding rather than empirical observation, as has been the case in toxicology. > Advanced human-specific disease models. In addition to a stra tegic and integrated knowledgebased exploitation of omics tools and the introduction of the AOP concept, we further propose a strong focus on humanspecific models. Advanced humanspecific cell and tissuebased models (e.g., Singh et al. 2011) and nextgeneration tools are making possible a fuller, dynamic comprehension of disease pathophysiology and a more reliable and costeffective drug discovery process (Muotri 2015). > Humaninduced pluripotent stem cell technology offers unique access to healthy as well as patient and diseasespecific in vitro cell models (Bellin et al. 2012). This could help achieve the holy grail of Figure 1. Integrating data on extrinsic and intrinsic causes of disease using systems biology provides a more comprehensive understanding of human illnesses. The adverse outcome pathway (AOP) concept links exposure, via chemical structure (or structures), the molecular initiating event, and key events, to an adverse outcome.

[10] Neurodevelopmental models of transcription factor 4 deficiency converge on a common ion channel as a potential therapeutic target for Pitt Hopkins syndrome

Authors: Matthew D. Rannals, S. Page, Morganne N. Campbell, Ryan A. Gallo, Brent Mayfield et al.
Year: 2016
Venue: Rare Diseases
URL: https://www.semanticscholar.org/paper/5527675a93315291579d926c05b804d7c82e2090
DOI: 10.1080/21675511.2016.1220468
PMID: 28032012
PMCID: 5154382
Citations: 26
Influential citations: 2
Summary: It is demonstrated that haploinsufficiency of TCF4 lead to the ectopic expression of two ion channels, Scn10a and Kcnq1, which indicates SCN10a is a potential therapeutic target for Pitt-Hopkins syndrome.
Evidence snippets:
Snippet 1 (score: 0.448) > Determining the underlying mechanisms of pathophysiology for rare diseases, as well as for more common disorders, is a formidable challenge. Here, and in our recent article, 13 we have described a system for phenotype discovery in a rare disease model that utilizes a novel molecular profiling method we term iTRAP that is capable of identifying candidate molecular mechanisms underlying pathophysiological phenotypes. > By comparing a cell autonomous TCF4 haploinsufficiency rat model to a PTHS mouse model, we identified a common electrophysiological phenotype that is at least partially caused by inappropriate expression of Scn10a, a voltage-gated sodium channel. We now consider SCN10a to be a potential therapeutic target for PTHS. Further experiments are required to determine if these phenotypes and molecular mechanisms observed at the cellular level can be successfully translated to the level of mouse behavior, to human biology, and ultimately to the development of therapeutic agents.

[11] Changes in Serum Proteomic Profiles at Different Stages of Pregnancy Toxemia in Goats

Authors: M. Uzti̇mür, C. N. Ünal, Gurler Akpinar
Year: 2025
Venue: Journal of Veterinary Internal Medicine
URL: https://www.semanticscholar.org/paper/4b9c488b5dbd65d7b26fd2ad9aed70e8c4b59942
DOI: 10.1111/jvim.70139
PMID: 40492724
PMCID: 12150350
Summary: Understanding the serum proteome profiles of goats with pregnancy toxemia might help identify the proteomes and pathways responsible for the development of this disease and improve diagnosis and treatment.
Evidence snippets:
Snippet 1 (score: 0.444) > The pathophysiology and progression of this disease are not fully understood. > Traditional biomedical research has focused on the analysis of single genes, proteins, metabolites, or metabolic pathways in diseases. This molecular reductionist approach is based on the assumption that identifying genetic variations and molecular components will lead to new treatments for diseases [13][14][15][16]. However, many diseases are complex and multifactorial, and in order to determine the phenotype of such diseases, it is necessary to understand the changes that occur in more than one gene, pathway, protein, or metabolite at the cellular, tissue, and organismal levels [17][18][19]. Therefore, in recent years, proteomics, as one field of multi-omics technologies, has helped in evaluating the complex pathogenetic mechanisms of different diseases from a broad perspective and has made substantial contributions [20,21]. In veterinary medicine, proteomic analysis of metabolic diseases such as ketosis [16], hypocalcemia [22], and fatty liver [23] in dairy cows has contributed valuable insights for the definition of new pathophysiological pathways and new diagnosis and treatment protocols for these diseases. The proteomic approach can contribute importantly to a broad and detailed understanding of the changes that occur at the organismal level associated with the increase in BHBA concentration in goats with pregnancy toxemia. Our aim was to evaluate the serum protein profiles of goats with SPT or CPT using proteomic techniques to determine the proteomic profiles of these animals and to identify the relevant pathophysiological mechanisms.

[12] Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions

Authors: C. Qin, Sheng Yang, Yun-hui Chu, Hang Zhang, Xiaoyi Pang et al.
Year: 2022
Venue: Signal Transduction and Targeted Therapy
URL: https://www.semanticscholar.org/paper/c228d67d7d6468e6610bf3880e81d8510ed5a25b
DOI: 10.1038/s41392-022-01064-1
PMID: 35794095
PMCID: 9259607
Citations: 682
Influential citations: 17
Summary: This review elucidated potential molecular mechanisms and related signaling pathways underlying ischemic stroke, and summarize the therapeutic approaches targeted various pathophysiology, with particular reference to clinical trials and future prospects for treating isChemic stroke.
Evidence snippets:
Snippet 1 (score: 0.443) > Ischemic stroke is caused primarily by an interruption in cerebral blood flow, which induces severe neural injuries, and is one of the leading causes of death and disability worldwide. Thus, it is of great necessity to further detailly elucidate the mechanisms of ischemic stroke and find out new therapies against the disease. In recent years, efforts have been made to understand the pathophysiology of ischemic stroke, including cellular excitotoxicity, oxidative stress, cell death processes, and neuroinflammation. In the meantime, a plethora of signaling pathways, either detrimental or neuroprotective, are also highly involved in the forementioned pathophysiology. These pathways are closely intertwined and form a complex signaling network. Also, these signaling pathways reveal therapeutic potential, as targeting these signaling pathways could possibly serve as therapeutic approaches against ischemic stroke. In this review, we describe the signaling pathways involved in ischemic stroke and categorize them based on the pathophysiological processes they participate in. Therapeutic approaches targeting these signaling pathways, which are associated with the pathophysiology mentioned above, are also discussed. Meanwhile, clinical trials regarding ischemic stroke, which potentially target the pathophysiology and the signaling pathways involved, are summarized in details. Conclusively, this review elucidated potential molecular mechanisms and related signaling pathways underlying ischemic stroke, and summarize the therapeutic approaches targeted various pathophysiology, with particular reference to clinical trials and future prospects for treating ischemic stroke.

[13] The use of intra-cellular signaling pathways in anesthesiology and pain medicine field.

Authors: J. Joo
Year: 2009
Venue: Korean journal of anesthesiology
URL: https://www.semanticscholar.org/paper/d20f7ea110adebeb95be021611d90522a87a42c1
DOI: 10.4097/kjae.2009.57.3.277
PMID: 30625873
Citations: 1
Summary: If efforts are focused on applying the new cellular and molecular biologic research, these efforts could identify the mechanism of diseases and help develop new drugs in the field of anesthesiology and pain medicine.
Evidence snippets:
Snippet 1 (score: 0.442) > At the level of individual cells, signaling is crucial in cell division, differentiation, metabolic control and death. Reception of the signals depends on receptor proteins that are usually at the cell surface, and these receptor proteins bind the signal molecule. The binding activates the receptor, which in turn activates one or more of the intra-cellular signaling pathways. These relay chains of molecules, mainly intra-cellular signaling proteins, process the signal inside the receiving cell and distribute it to the appropriate intra-cellular targets. Cell signaling pathways are involved in the pathophysiology of many diseases and also in the mechanisms of action of many drugs, including local and general anesthetics. Knowledge of the basic cell signaling mechanisms is essential for understanding many of the pathophysiologic and pharmacologic mechanisms. Therefore, if we focus on applying the new cellular and molecular biologic research, these efforts could identify the mechanism of diseases and help develop new drugs in the field of anesthesiology and pain medicine.

[14] A framework for integrating evidence to assess hazards and risk

Authors: Sandra I Sulsky, Tracy Greene, P. Gentry
Year: 2024
Venue: Critical Reviews in Toxicology
URL: https://www.semanticscholar.org/paper/dbbeed8f2ab91451a96ae1d432e50cfb0277a371
DOI: 10.1080/10408444.2024.2342447
PMID: 38808643
Citations: 1
Summary: This novel evidence integration framework (EIF) provides a method for synthesizing data from comprehensive, systematic, quality-based assessments of the epidemiological and toxicological literature, including in vivo and in vitro mechanistic studies, providing a method to support evidence synthesis.
Evidence snippets:
Snippet 1 (score: 0.439) > Similarly, toxicological studies may be based on a hypothesis regarding relationships between exposures and outcomes without a solid evidence base.These factors complicate the synthesis of the data and can make it difficult to identify concordance between human health outcomes and the types of endpoints studied toxicologically.The value of the EIF is its inclusion of all available information, and its explicit discussion of sources of uncertainty and the effect of uncertainty on the conclusions that can be drawn. > The disease-based component of the EIF is driven by the diseases observed and evaluated in humans and is enhanced by an understanding of the pathophysiology of those specific diseases.It allows for consideration of endpoints that mark the progression of disease, if they are measurable in humans or animals, but it does not address potential initiating events or include assay results at the cellular level that are not linked to identifiable human pathology.In addition, endpoints that share common biological mechanisms, but not similar pathophysiological manifestations, are often considered relevant to different disease groupings.Therefore, applying the disease-based categorization system requires an additional integrative step to identify common modes of action across specific diseases within a group. > In contrast, the mechanism-based component of the EIF accounts for general mechanisms of disease causation and can incorporate assay results at the cellular level that have been used as potential indicators of disease risk (e.g.Ames assay).Poor or incomplete understanding of the mechanisms leading to diseases proposed to be associated with exposure will increase the level of uncertainty of the conclusions.Recognizing and delineating these uncertainties in basic medical and scientific knowledge may direct future research decisions. > As much as the EIF aims to be objective and to make explicit the processes for rating and weighting the available evidence, some qualitative, subjective elements remain.Professional judgment is required to rate the quality of the underlying studies and to determine which human and toxicological endpoints are related sufficiently to be grouped together.The disease-based approach to organizing the toxicological data relies on the original authors' definitions of outcomes and their study purposes, which influence the conclusions drawn from the evidence integration.

[15] Mitochondrial Dysfunction in Diabetes: Shedding Light on a Widespread Oversight

Authors: F. Iheagwam, A. J. Joseph, E. D. Adedoyin, Olawumi Toyin Iheagwam, Samuel Akpoyowvare Ejoh
Year: 2025
Venue: Pathophysiology
URL: https://www.semanticscholar.org/paper/dbf8042761c1a5fc50f8cd894cc498505abac7cb
DOI: 10.3390/pathophysiology32010009
PMID: 39982365
PMCID: 12077258
Citations: 22
Summary: This review aims to elucidate the complex link between mitochondrial dysfunction and diabetes, covering the spectrum of diabetes types, the role of mitochondria in insulin resistance, highlighting pathophysiological mechanisms, mitochondrial DNA damage, and altered mitochondrial biogenesis and dynamics.
Evidence snippets:
Snippet 1 (score: 0.438) > The landscape of DM research is continuously evolving, with emerging technologies and approaches offering new insights into the pathophysiology of the disease and potential therapeutic targets. Advancements in omics technologies, encompassing genomes, transcriptomics, proteomics, and metabolomics, have transformed the molecular mechanisms underlying DM [134]. High-throughput sequencing techniques enable comprehensive analysis of genetic variants, gene expression profiles, protein abundance, and metabolite levels associated with DM and its complications [135]. Single-cell omics approaches provide unprecedented resolution and granularity, allowing researchers to dissect cellular heterogeneity and identify novel cell types, subpopulations, and signalling pathways involved in DM pathogenesis. Integrating multi-omics data sets offers a systems-level perspective of DM, unravelling complex networks of molecular interactions and regulatory circuits underlying disease progression [136]. > In addition to omics technologies, advances in imaging modalities, such as MRI, PET, and optical imaging, enable non-invasive visualisation and quantification of metabolic, functional, and structural changes. Molecular imaging probes targeting specific biomarkers and metabolic pathways provide valuable insights into disease mechanisms and treatment responses in preclinical and clinical settings [85]. Despite significant progress in DM research, numerous unanswered questions and knowledge gaps persist, hindering the ability to develop effective prevention and treatment strategies. Key areas requiring further investigation include the role of epigenetics, environmental factors, and the microbiome in DM susceptibility and progression. Moreover, the interaction between environmental cues and genetic predisposition remains incompletely understood, highlighting the need for comprehensive multi-omics studies and large-scale epidemiological analyses to identify gene-environment interactions and modifiable risk factors for DM [137]. Furthermore, the heterogeneity of DM phenotypes and clinical outcomes poses a challenge for personalised medicine approaches, necessitating robust biomarkers and predictive models to stratify patients based on disease subtypes, prognosis, and treatment response [138].

[16] Extracellular Cold-Inducible RNA-Binding Protein: Progress from Discovery to Present

Authors: M. Aziz, I. Chaudry, Ping Wang
Year: 2025
Venue: International Journal of Molecular Sciences
URL: https://www.semanticscholar.org/paper/c47336a8ca38d2a39d9f4ae2bc3a3bfd47063ccb
DOI: 10.3390/ijms26083524
PMID: 40332009
PMCID: 12026706
Citations: 3
Summary: The molecular, cellular, and immunological mechanisms through which eCIRP contributes to disease progression, and the potential therapeutic strategies targeting eCIRP in preclinical models of inflammatory and ischemic diseases are explored.
Evidence snippets:
Snippet 1 (score: 0.438) > Extracellular cold-inducible RNA-binding protein (eCIRP) is a critical damage-associated molecular pattern (DAMP) that drives inflammation and tissue injury in hemorrhagic and septic shock, and has emerged as a promising therapeutic target. Since then, extensive research using preclinical models of diseases and patient materials has explored eCIRP’s role in driving inflammatory responses and its potential as a biomarker. The main objective of this comprehensive review is to provide a detailed overview of eCIRP, covering its discovery, role in disease pathophysiology, mechanisms of release and action, potential as a biomarker, and therapeutic strategies targeting eCIRP in preclinical models of inflammatory and ischemic diseases. We examine the molecular, cellular, and immunological mechanisms through which eCIRP contributes to disease progression, and explore both well-established and emerging areas of research. Furthermore, we discuss potential therapeutic strategies targeting eCIRP across a broad spectrum of inflammatory conditions, including shock, ischemia–reperfusion injury, neurodegenerative diseases, and radiation injury.

[17] Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)

Authors: Qian-rui Huang, Yue Le, Shusheng Li, Yi Bian
Year: 2024
Venue: Respiratory Research
URL: https://www.semanticscholar.org/paper/886cb171076bcc2ba770b87ab0fae9baa96120ba
DOI: 10.1186/s12931-024-02678-5
PMID: 38218783
PMCID: 10788036
Citations: 57
Influential citations: 1
Summary: The pathogenesis and pathophysiology of ARDS that involve dysregulated inflammation, alveolar-capillary barrier dysfunction, impaired alveolar fluid clearance and oxidative stress are described and the emerging therapeutic strategies that show exciting promise are discussed.
Evidence snippets:
Snippet 1 (score: 0.437) > Acute respiratory distress syndrome (ARDS) is a common condition associated with critically ill patients, characterized by bilateral chest radiographical opacities with refractory hypoxemia due to noncardiogenic pulmonary edema. Despite significant advances, the mortality of ARDS remains unacceptably high, and there are still no effective targeted pharmacotherapeutic agents. With the outbreak of coronavirus disease 19 worldwide, the mortality of ARDS has increased correspondingly. Comprehending the pathophysiology and the underlying molecular mechanisms of ARDS may thus be essential to developing effective therapeutic strategies and reducing mortality. To facilitate further understanding of its pathogenesis and exploring novel therapeutics, this review provides comprehensive information of ARDS from pathophysiology to molecular mechanisms and presents targeted therapeutics. We first describe the pathogenesis and pathophysiology of ARDS that involve dysregulated inflammation, alveolar-capillary barrier dysfunction, impaired alveolar fluid clearance and oxidative stress. Next, we summarize the molecular mechanisms and signaling pathways related to the above four aspects of ARDS pathophysiology, along with the latest research progress. Finally, we discuss the emerging therapeutic strategies that show exciting promise in ARDS, including several pharmacologic therapies, microRNA-based therapies and mesenchymal stromal cell therapies, highlighting the pathophysiological basis and the influences on signal transduction pathways for their use.

[18] Benefits of animal models to understand the pathophysiology of depressive disorders.

Authors: B. Czéh, M. Simón
Year: 2020
Venue: Progress in neuro-psychopharmacology & biological psychiatry
URL: https://www.semanticscholar.org/paper/8caa4b74966abb2fe5b324dd454ebcb81a5f7b6a
DOI: 10.1016/j.pnpbp.2020.110049
PMID: 32735913
Citations: 24
Summary: It is argued, that despite their evident imperfections, these models provide invaluable help to understand cellular and molecular mechanisms contributing to the development of MDD.
Evidence snippets:
Snippet 1 (score: 0.436) > Based on our current understanding it appears that all major cell types of the CNS contribute to the pathophysiology of MDD. Both excitatory and inhibitory neurons, as well as the glial cells are involved, but we know very little about the sequence of events. The key questions are: Which cell type is the weakest link? Is there a specific cellular cascade mechanism leading to the pathophysiology, or all the cellular changes are taking place parallel to each other? It is still not clear whether all these cellular alterations are evidences of cellular "damage" or some of them represent compensatory mechanisms. Longitudinal studies focusing on several cell types simultaneously may yield answers to these questions. > Animal models for mental disorders received heavy criticisms and has been occasionally named as scapegoats for the lack of developments in psychiatric therapeutics. Despite all their significant shortcomings these models are extensively used in academic research and drug development. We should accept that none of the models can mimic all aspects of this complex disease, but they can provide opportunities to understand the specific genetic, molecular and cellular mechanisms contributing to the development of MDD.

[19] Navigating the disease landscape: knowledge representations for contextualizing molecular signatures

Authors: M. Saqi, A. Lysenko, Yi-Ke Guo, T. Tsunoda, C. Auffray
Year: 2018
Venue: Briefings in Bioinformatics
URL: https://www.semanticscholar.org/paper/70d6d85cc0f6f5fa4347d7a6135a322c81a41945
DOI: 10.1093/bib/bby025
PMID: 29684165
PMCID: 6556902
Citations: 14
Summary: This review discusses knowledge representations that can be useful to explore the biological context of molecular signatures, in particular three main approaches, namely, pathway mapping approaches, molecular network centric approaches and approaches that represent biological statements as knowledge graphs.
Evidence snippets:
Snippet 1 (score: 0.431) > Owing to technological advances allowing rapid and low-cost profiling of biological systems, multiple types of omics data are now routinely collected from patient cohorts in studies of human diseases. These data can lead to a new taxonomy of disease [1]. Diseases that were previously considered to be single homogeneous conditions may in fact be collections of several disease subtypes. Identification of subtypes allows targeting of the underlying molecular processes involved in the particular form of disease associated with the subtype, and can lead to more personalized therapeutic strategies. A major challenge for translational medicine informatics is the effective exploitation of these data types to develop a more complete picture of the disease, in particular a description of how changes at the molecular level are associated with the disease mechanism and disease pathophysiology. The molecular profiles by themselves do not, in general, offer immediate insight into the mechanism of disease or the underlying causes, and may be of limited utility for suggesting targets for therapeutic intervention. Putting these molecular patterns into a broader biological context represents a useful approach for understanding the underlying themes involved in the disease pathology, and this involves integrating the molecular profiles with other data types, including pathways, cellular and physiological data. > Together with data warehousing and data analytics, the contextualization of data emerging from high-throughput experiments is an important component of a translational informatics pipeline. The contextualization of experimental data is facilitated by mapping the data to background knowledge, which can include information at multiple levels of granularity. An effective representation of the disease needs to relate diseasespecific information to background knowledge so as to help researchers identify how dysfunctional proteins, pathways or other molecular processes lead to the cellular or physiological changes contributing to its aetiology. > Here, we review efforts to represent the context of diseaseimplicated genes, and we suggest that they can be divided into three broad themes, namely, pathway-centric, molecular network centric and approaches that represent biological statements as a knowledge graph (Table 1). We describe the advantages and drawbacks of the different representations. We do not discuss the details by which the genes are mapped to pathways or networks (for review of approaches to data interpretation, see for example [2]).

Notes

This provider combines search_papers_by_relevance with snippet_search.
No synthesis or second-stage model call is performed.

{ }

Source YAML

click to show

name: Thallium Poisoning
creation_date: "2026-03-17T21:02:44Z"
updated_date: "2026-04-14T20:55:00Z"
category: Environmental
categories:
- Toxic Exposure Disorder
- Heavy Metal Poisoning
- Environmental Health Disorder
synonyms:
- thallium intoxication
description: >-
  Thallium poisoning is a toxic condition caused by acute or chronic exposure to
  thallium, a highly toxic heavy metal encountered through industrial thallium
  salts, contaminated medicines or foods, older rodenticide use, and deliberate
  poisoning. Thallium is rapidly and nearly completely absorbed, distributes
  systemically, enters cells by mimicking potassium, interferes with energy
  production, inhibits sodium-potassium ATPase, and binds sulfhydryl-containing
  molecules. The resulting multisystem toxicity most characteristically causes a
  painful ascending peripheral neuropathy and delayed alopecia, often preceded
  by gastrointestinal symptoms and followed by persistent neurologic sequelae in
  severe cases.
disease_term:
  preferred_term: thallium poisoning
  term:
    id: MONDO:0041996
    label: thallium poisoning
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0041996
      label: thallium poisoning
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: Primary MONDO disease identifier for thallium poisoning.
classifications:
  harrisons_chapter:
  - classification_value: nervous system disorder
    evidence:
    - reference: PMID:14579545
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The major manifestations of toxicity consist of a rapidly progressive, ascending, extremely painful sensory neuropathy and alopecia."
      explanation: Supports classifying thallium poisoning within nervous system disorders because its dominant clinical manifestations center on severe neurotoxicity.
definitions:
- name: Clinical toxic exposure syndrome definition for thallium poisoning
  definition_type: CASE_DEFINITION
  description: >-
    Thallium poisoning is a multisystem toxic syndrome caused by exposure to
    thallium salts, with especially characteristic painful peripheral
    neuropathy and alopecia superimposed on broader gastrointestinal,
    cutaneous, neuropsychiatric, and visceral toxicity.
  scope: Disease-level clinical framing across acute and delayed presentations
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major manifestations of toxicity consist of a rapidly progressive, ascending, extremely painful sensory neuropathy and alopecia."
    explanation: Supports the defining clinical syndrome of thallium poisoning as a toxic disorder centered on painful neuropathy and alopecia.
  - reference: PMID:6338655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The symptomatology of its toxicity is usually nonspecific due to the multi-organ involvement."
    explanation: Supports framing the disorder as a multisystem toxicity rather than an isolated neurologic or dermatologic disease.
- name: Practical diagnostic definition for suspected thallium poisoning
  definition_type: DIAGNOSTIC_CRITERIA
  description: >-
    Practical diagnosis relies on recognizing the combination of
    gastrointestinal, neurologic, and cutaneous findings and confirming
    exposure with blood or urine thallium measurement.
  scope: Clinical recognition and laboratory confirmation in suspected poisoning
  evidence:
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The correct diagnosis was confirmed by blood and urine thallium assays."
    explanation: Supports laboratory confirmation of suspected thallium poisoning using blood and urine assays.
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thallium intoxication may have been initially identified if neurologic symptoms had occurred concurrently with gastrointestinal and cutaneous symptoms."
    explanation: Supports the practical diagnostic pattern of concurrent neurologic, gastrointestinal, and cutaneous manifestations.
parents:
- heavy metal poisoning
has_subtypes:
- name: Acute Thallium Poisoning
  description: >-
    Acute thallium poisoning follows a higher-dose ingestion or other intense
    exposure and presents first with gastrointestinal and neuropsychiatric
    symptoms, with severe cases progressing to convulsions, coma, pulmonary
    injury, and multi-organ failure.
  evidence:
  - reference: PMID:6338655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The initial symptoms of thallium poisoning may include fever, gastrointestinal problems, delirium, convulsions and coma."
    explanation: Supports an acute presentation marked by early gastrointestinal and neurologic toxicity.
  - reference: PMID:40884943
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The cause of death in this case was thus determined to be ARDS caused by acute Tl poisoning."
    explanation: Supports that severe acute poisoning can progress to fatal pulmonary injury and multi-organ failure.
- name: Delayed neurocutaneous thallium poisoning
  description: >-
    After the initial exposure phase, patients commonly evolve into a delayed
    neurocutaneous syndrome with painful polyneuropathy, alopecia, skin and
    nail changes, and persistent neurologic sequelae.
  evidence:
  - reference: PMID:6338655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Symptoms may appear rapidly, but more commonly the acute toxicity subsides to be replaced by a gradual development of mild gastrointestinal disturbances, polyneuritis, encephalopathy, tachycardia, skin eruptions, stomatitis, atrophic changes of the skin, nail changes (Mee's lines), and skin hyperesthesia (mainly in the soles of the feet and the tibia)."
    explanation: Supports a delayed subacute phase dominated by progressive neurocutaneous manifestations after the earliest toxic presentation.
progression:
- phase: Early gastrointestinal and systemic prodrome
  notes: >-
    Thallium poisoning often begins with nonspecific gastrointestinal and
    systemic symptoms that can be mistaken for more common acute illnesses.
  evidence:
  - reference: PMID:6338655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The initial symptoms of thallium poisoning may include fever, gastrointestinal problems, delirium, convulsions and coma."
    explanation: Supports an early prodromal phase with gastrointestinal and systemic toxicity.
- phase: Delayed neurologic and cutaneous phase
  notes: >-
    Over subsequent days to weeks, a more recognizable syndrome of painful
    neuropathy and alopecia emerges and may leave residual neurologic injury.
  evidence:
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic damage represented the main sequelae of thallium poisoning in our present case report."
    explanation: Supports later neurologic dominance and residual sequelae in the disease course.
  - reference: PMID:6338655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In humans the most characteristic sign of thallium toxicity is alopecia which usually appears in cases when death is delayed for 15-20 days."
    explanation: Supports alopecia as a delayed clinical feature emerging after the earliest toxic phase.
pathophysiology:
- name: Gastrointestinal absorption of thallium
  description: >-
    Thallium salts are rapidly and nearly completely absorbed after exposure,
    with gastrointestinal ingestion being the most common route to clinically
    important poisoning.
  locations:
  - preferred_term: gastrointestinal tract
    term:
      id: UBERON:0005409
      label: alimentary part of gastrointestinal system
  biological_processes:
  - preferred_term: transmembrane transport
    term:
      id: GO:0055085
      label: transmembrane transport
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thallium salts are rapidly and nearly completely absorbed by virtually all routes, with gastrointestinal exposure being the most common route to produce toxicity."
    explanation: Supports efficient thallium absorption and the importance of gastrointestinal exposure in establishing poisoning.
  downstream:
  - target: Systemic thallium distribution
    description: Absorbed thallium rapidly redistributes throughout the body and reaches multiple target organs.
    evidence:
    - reference: PMID:31335706
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Thallium compounds can accumulate in the human body and be rapidly distributed throughout it, including in the skin and hair."
      explanation: Supports the transition from gastrointestinal absorption to rapid systemic distribution into multiple tissues.
- name: Systemic thallium distribution
  description: >-
    After absorption, thallium rapidly distributes throughout the body,
    including nervous tissue, skin, and hair, enabling multisystem toxicity.
  biological_processes:
  - preferred_term: abnormal localization
    modifier: ABNORMAL
    term:
      id: GO:0051179
      label: localization
  evidence:
  - reference: PMID:31335706
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thallium compounds can accumulate in the human body and be rapidly distributed throughout it, including in the skin and hair."
    explanation: Directly supports widespread systemic distribution of thallium after absorption.
  downstream:
  - target: Potassium-mimetic cellular uptake
    description: Distributed thallium enters cells by exploiting potassium-like physicochemical properties.
    evidence:
    - reference: PMID:14579545
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Thallium enters cells by a unique process governed by its similarity in charge and ionic radius to potassium."
      explanation: Supports progression from systemic distribution to potassium-mimetic cellular uptake.
  - target: Keratin affinity and appendage accumulation
    description: Distributed thallium also accumulates in keratin-rich tissues such as hair and nails.
    evidence:
    - reference: PMID:31335706
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Thallium compounds can accumulate in the human body and be rapidly distributed throughout it, including in the skin and hair."
      explanation: Supports a downstream branch from systemic distribution into skin and hair compartments.
- name: Potassium-mimetic cellular uptake
  description: >-
    Thallium enters cells through potassium-handling pathways because its ionic
    charge and radius closely resemble potassium, disrupting intracellular ionic
    homeostasis.
  biological_processes:
  - preferred_term: response to potassium ion
    term:
      id: GO:0035864
      label: response to potassium ion
  - preferred_term: potassium ion transport
    modifier: DYSREGULATED
    term:
      id: GO:0006813
      label: potassium ion transport
  - preferred_term: intracellular monoatomic ion homeostasis
    modifier: DYSREGULATED
    term:
      id: GO:0006873
      label: intracellular monoatomic ion homeostasis
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thallium enters cells by a unique process governed by its similarity in charge and ionic radius to potassium."
    explanation: Directly supports potassium-mimetic cellular uptake as a core toxicokinetic mechanism.
  downstream:
  - target: Bioenergetic failure
    description: Intracellular thallium disrupts core pathways of ATP generation.
    evidence:
    - reference: PMID:14579545
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "thallium interferes with energy production at essential steps in glycolysis, the Krebs cycle, and oxidative phosphorylation."
      explanation: Supports progression from cellular thallium uptake to direct disruption of bioenergetic pathways.
  - target: Sodium-potassium ATPase inhibition
    description: Intracellular thallium interferes with sodium-potassium ATPase activity and membrane ion homeostasis.
    evidence:
    - reference: PMID:14579545
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Additional effects include inhibition of sodium-potassium-adenosine triphosphatase"
      explanation: Supports sodium-potassium ATPase inhibition as a distinct downstream consequence of cellular thallium uptake.
  - target: Sulfhydryl-dependent molecular binding
    description: Intracellular thallium also binds sulfhydryl-containing molecules and perturbs protein function.
    evidence:
    - reference: PMID:14579545
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "binding to sulfhydryl groups."
      explanation: Supports sulfhydryl binding as a separable downstream molecular lesion after thallium enters cells.
- name: Bioenergetic failure
  description: >-
    Once inside cells, thallium impairs glycolysis, the Krebs cycle, and
    oxidative phosphorylation, creating a broad failure of energy production
    that contributes to multi-organ toxicity.
  biological_processes:
  - preferred_term: glycolytic process
    modifier: DECREASED
    term:
      id: GO:0006096
      label: glycolytic process
  - preferred_term: tricarboxylic acid cycle
    modifier: DECREASED
    term:
      id: GO:0006099
      label: tricarboxylic acid cycle
  - preferred_term: oxidative phosphorylation
    modifier: DECREASED
    term:
      id: GO:0006119
      label: oxidative phosphorylation
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "thallium interferes with energy production at essential steps in glycolysis, the Krebs cycle, and oxidative phosphorylation."
    explanation: Supports mitochondrial and cytosolic bioenergetic failure as a central mechanism of thallium toxicity.
  downstream:
  - target: Peripheral nervous system injury
    description: Energetically vulnerable peripheral nerves develop toxic injury with painful sensorimotor dysfunction.
    evidence:
    - reference: PMID:14579545
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "The major manifestations of toxicity consist of a rapidly progressive, ascending, extremely painful sensory neuropathy and alopecia."
- name: Sodium-potassium ATPase inhibition
  description: >-
    Thallium inhibits sodium-potassium ATPase, destabilizing membrane ion
    homeostasis and contributing to autonomic and central neurotoxicity.
  biological_processes:
  - preferred_term: sodium ion transport
    modifier: DECREASED
    term:
      id: GO:0006814
      label: sodium ion transport
  - preferred_term: potassium ion transport
    modifier: DECREASED
    term:
      id: GO:0006813
      label: potassium ion transport
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional effects include inhibition of sodium-potassium-adenosine triphosphatase"
    explanation: Directly supports sodium-potassium ATPase inhibition as a distinct toxic mechanism in thallium poisoning.
  downstream:
  - target: Autonomic and central neurotoxicity
    description: Ion-pump failure contributes to dysautonomia and central nervous system dysfunction in more severe poisoning.
    evidence:
    - reference: PMID:14579545
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Many other findings such as an autonomic neuropathy, cranial nerve abnormalities, altered mental status, motor weakness, cardiac, hepatic, and renal effects are described, but are less specific."
      explanation: Supports a downstream relationship from ATPase inhibition to autonomic and central neurologic dysfunction, though the abstract does not isolate a single direct intermediate.
- name: Sulfhydryl-dependent molecular binding
  description: >-
    Thallium binds sulfhydryl-containing molecules, perturbing protein function
    and contributing to downstream neurotoxicity.
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "binding to sulfhydryl groups."
    explanation: Supports sulfhydryl binding as a distinct molecular lesion in thallium toxicity.
  downstream:
  - target: Peripheral nervous system injury
    description: Sulfhydryl-dependent molecular dysfunction contributes to progressive peripheral nerve injury.
    evidence:
    - reference: PMID:14579545
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "The major manifestations of toxicity consist of a rapidly progressive, ascending, extremely painful sensory neuropathy and alopecia."
      explanation: Supports downstream contribution to peripheral neurotoxicity, although the omitted intermediates are not detailed in the abstract.
- name: Peripheral nervous system injury
  description: >-
    Thallium poisoning prominently injures the peripheral nervous system,
    producing a rapidly progressive, extremely painful ascending neuropathy and
    leaving persistent neurologic sequelae in some survivors.
  cell_types:
  - preferred_term: peripheral nervous system neuron
    term:
      id: CL:2000032
      label: peripheral nervous system neuron
  locations:
  - preferred_term: peripheral nervous system
    term:
      id: UBERON:0000010
      label: peripheral nervous system
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major manifestations of toxicity consist of a rapidly progressive, ascending, extremely painful sensory neuropathy and alopecia."
    explanation: Supports painful ascending sensory neuropathy as the dominant neurologic expression of thallium toxicity.
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Neurologic damage represented the main sequelae of thallium poisoning in our present case report."
    explanation: Supports persistent neurologic injury as an important consequence of thallium neurotoxicity.
  downstream:
  - target: Peripheral neuropathy
    description: Peripheral nerve injury causes the characteristic painful ascending neuropathy.
    evidence:
    - reference: PMID:14579545
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "The major manifestations of toxicity consist of a rapidly progressive, ascending, extremely painful sensory neuropathy and alopecia."
      explanation: Directly supports peripheral nerve injury as the basis of the characteristic neuropathy phenotype.
- name: Autonomic and central neurotoxicity
  description: >-
    In more severe poisoning, thallium toxicity extends beyond painful
    peripheral neuropathy into autonomic dysfunction and central nervous system
    injury.
  cell_types:
  - preferred_term: autonomic neuron
    term:
      id: CL:0000107
      label: autonomic neuron
  - preferred_term: central nervous system neuron
    term:
      id: CL:2000029
      label: central nervous system neuron
  locations:
  - preferred_term: autonomic nervous system
    term:
      id: UBERON:0002410
      label: autonomic nervous system
  - preferred_term: central nervous system
    term:
      id: UBERON:0001017
      label: central nervous system
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Many other findings such as an autonomic neuropathy, cranial nerve abnormalities, altered mental status, motor weakness, cardiac, hepatic, and renal effects are described, but are less specific."
    explanation: Supports autonomic and central neurologic toxicity as a distinct branch of thallium poisoning.
  - reference: PMID:31335706
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Some patients with delayed admission had significant symptoms associated with central nervous system damage"
    explanation: Supports central nervous system injury as a clinically important branch in delayed or severe poisoning.
  downstream:
  - target: Constipation
    description: Autonomic neurotoxicity contributes to characteristic lower-gastrointestinal dysmotility.
    evidence:
    - reference: PMID:14579545
      supports: PARTIAL
      evidence_source: HUMAN_CLINICAL
      snippet: "Unlike exposure to most metal salts, gastrointestinal symptoms of thallium toxicity are relatively minor, and constipation is more characteristic than diarrhoea."
      explanation: Supports constipation as a characteristic downstream expression of the broader neurotoxic syndrome, likely with autonomic contribution.
  - target: Altered mental status
    description: Severe neurotoxicity can extend to central neurologic dysfunction and encephalopathy.
    evidence:
    - reference: PMID:14579545
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Many other findings such as an autonomic neuropathy, cranial nerve abnormalities, altered mental status, motor weakness, cardiac, hepatic, and renal effects are described, but are less specific."
      explanation: Supports altered mental status as a downstream manifestation of central neurotoxicity.
- name: Keratin affinity and appendage accumulation
  description: >-
    Thallium has affinity for keratin-rich tissues and accumulates in hair and
    nails, establishing a distinct appendage-toxicity branch of poisoning.
  cell_types:
  - preferred_term: keratinocyte
    term:
      id: CL:0000312
      label: keratinocyte
  locations:
  - preferred_term: skin of body
    term:
      id: UBERON:0002097
      label: skin of body
  - preferred_term: hair shaft
    term:
      id: UBERON:0002074
      label: hair shaft
  evidence:
  - reference: PMID:28761262
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thallium does not have an internal anatomic reservoir, but has an affinity to keratin."
    explanation: Supports keratin affinity and appendage accumulation as a distinct toxic branch.
  downstream:
  - target: Hair follicle toxicity
    description: Keratin-associated accumulation contributes to direct hair follicle injury.
    evidence:
    - reference: PMID:28761262
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A trichogram revealed 95% of the hairs in dystrophic anagen status"
      explanation: Supports a downstream transition from appendage accumulation to direct hair follicle injury.
- name: Hair follicle toxicity
  description: >-
    Thallium causes dystrophic anagen injury in hair follicles, which then
    manifests clinically as delayed diffuse alopecia.
  cell_types:
  - preferred_term: hair follicle cell
    term:
      id: CL:0002559
      label: hair follicle cell
  locations:
  - preferred_term: hair follicle
    term:
      id: UBERON:0002073
      label: hair follicle
  - preferred_term: hair shaft
    term:
      id: UBERON:0002074
      label: hair shaft
  biological_processes:
  - preferred_term: hair follicle development
    modifier: DECREASED
    term:
      id: GO:0001942
      label: hair follicle development
  - preferred_term: hair cycle
    modifier: ABNORMAL
    term:
      id: GO:0042633
      label: hair cycle
  evidence:
  - reference: PMID:28761262
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A trichogram revealed 95% of the hairs in dystrophic anagen status"
    explanation: Supports direct hair follicle injury with dystrophic anagen changes in thallium poisoning.
  downstream:
  - target: Alopecia
    description: Hair follicle toxicity and keratin-associated accumulation lead to delayed diffuse alopecia.
    evidence:
    - reference: PMID:6338655
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In humans the most characteristic sign of thallium toxicity is alopecia which usually appears in cases when death is delayed for 15-20 days."
      explanation: Directly supports alopecia as a delayed downstream consequence of thallium hair toxicity.
phenotypes:
- name: Peripheral neuropathy
  category: Neurologic
  frequency: FREQUENT
  description: >-
    Thallium poisoning commonly causes a rapidly progressive, painful,
    ascending sensory-predominant peripheral neuropathy that may leave
    persistent neurologic deficits.
  phenotype_term:
    preferred_term: peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major manifestations of toxicity consist of a rapidly progressive, ascending, extremely painful sensory neuropathy and alopecia."
    explanation: Directly supports painful ascending peripheral neuropathy as a frequent hallmark phenotype.
- name: Alopecia
  category: Dermatologic
  frequency: FREQUENT
  description: >-
    Diffuse alopecia is a characteristic delayed manifestation of thallium
    poisoning and often becomes a key diagnostic clue after the initial toxic
    phase.
  phenotype_term:
    preferred_term: alopecia
    term:
      id: HP:0001596
      label: Alopecia
  evidence:
  - reference: PMID:6338655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In humans the most characteristic sign of thallium toxicity is alopecia which usually appears in cases when death is delayed for 15-20 days."
    explanation: Supports alopecia as the most characteristic delayed cutaneous sign of thallium poisoning.
- name: Abdominal pain
  category: Gastrointestinal
  frequency: FREQUENT
  description: >-
    Abdominal pain is a common early gastrointestinal manifestation and may
    precede the more specific neurocutaneous syndrome.
  phenotype_term:
    preferred_term: abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We found that polyneuropathy (82%), alopecia (68%), and abdominal pain (51%) were the most frequent clinical manifestations"
    explanation: Supports abdominal pain as one of the most frequent reported manifestations in thallium poisoning cases.
- name: Constipation
  category: Gastrointestinal
  frequency: OCCASIONAL
  description: >-
    Constipation is a characteristic gastrointestinal feature of thallium
    poisoning and may be more typical than diarrhea.
  phenotype_term:
    preferred_term: constipation
    term:
      id: HP:0002019
      label: Constipation
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Unlike exposure to most metal salts, gastrointestinal symptoms of thallium toxicity are relatively minor, and constipation is more characteristic than diarrhoea."
    explanation: Supports constipation as a characteristic gastrointestinal phenotype in thallium toxicity.
- name: Altered mental status
  category: Neurologic
  frequency: OCCASIONAL
  description: >-
    Severe poisoning can cause confusion, delirium, or other alterations in
    mental status alongside peripheral neurotoxicity.
  phenotype_term:
    preferred_term: confusion
    term:
      id: HP:0001289
      label: Confusion
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Many other findings such as an autonomic neuropathy, cranial nerve abnormalities, altered mental status, motor weakness, cardiac, hepatic, and renal effects are described, but are less specific."
    explanation: Supports altered mental status as a recognized but less specific neurologic manifestation.
environmental:
- name: Industrial thallium salt exposure
  description: >-
    Occupational or environmental exposure can occur through industrial thallium
    salts used in manufacturing processes.
  exposure_term:
    preferred_term: exposure to thallium
    term:
      id: ECTO:9001312
      label: exposure to thallium
    qualifiers:
    - predicate:
        preferred_term: has input
        term:
          id: RO:0002233
          label: has input
      value:
        preferred_term: thallium molecular entity
        term:
          id: CHEBI:37110
          label: thallium molecular entity
  environment_context:
    preferred_term: factory
    term:
      id: ENVO:01000536
      label: factory
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thallium salts have been used as medicinal agents, as key ingredients in a variety of manufacturing processes, and as a potent rodenticide."
    explanation: Supports industrial thallium salts as an important exposure source.
- name: Rodenticide exposure
  description: >-
    Thallium-containing rodenticides have historically caused accidental and
    intentional poisonings where access remained possible.
  exposure_term:
    preferred_term: exposure to thallium
    term:
      id: ECTO:9001312
      label: exposure to thallium
    qualifiers:
    - predicate:
        preferred_term: has input
        term:
          id: RO:0002233
          label: has input
      value:
        preferred_term: thallium molecular entity
        term:
          id: CHEBI:37110
          label: thallium molecular entity
    - predicate:
        preferred_term: has input
        term:
          id: RO:0002233
          label: has input
      value:
        preferred_term: rodenticide
        term:
          id: CHEBI:33288
          label: rodenticide
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thallium salts have been used as medicinal agents, as key ingredients in a variety of manufacturing processes, and as a potent rodenticide."
    explanation: Supports rodenticide use as a recognized exposure source for thallium poisoning.
- name: Coal combustion and cement manufacturing exposure
  description: >-
    Environmental thallium contamination can arise from industrial waste linked
    to coal combustion and cement manufacture.
  exposure_term:
    preferred_term: exposure to thallium
    term:
      id: ECTO:9001312
      label: exposure to thallium
    qualifiers:
    - predicate:
        preferred_term: has input
        term:
          id: RO:0002233
          label: has input
      value:
        preferred_term: thallium molecular entity
        term:
          id: CHEBI:37110
          label: thallium molecular entity
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "environmental concerns are growing, as thallium is a waste product of coal combustion and the manufacturing of cement."
    explanation: Supports coal combustion and cement manufacturing as environmental contamination sources.
- name: Contaminated alternative medicine exposure
  description: >-
    Contaminated traditional or alternative medicines can be an underrecognized
    source of acute thallium ingestion.
  exposure_term:
    preferred_term: exposure to thallium
    term:
      id: ECTO:9001312
      label: exposure to thallium
    qualifiers:
    - predicate:
        preferred_term: has input
        term:
          id: RO:0002233
          label: has input
      value:
        preferred_term: thallium molecular entity
        term:
          id: CHEBI:37110
          label: thallium molecular entity
    - predicate:
        preferred_term: has participant
        term:
          id: RO:0000057
          label: has participant
      value:
        preferred_term: digestive system
        term:
          id: UBERON:0001007
          label: digestive system
  evidence:
  - reference: PMID:28761262
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we report a case of acute, nonintentional thallium poisoning due to thallium-contaminated alternative medicine"
    explanation: Directly supports contaminated alternative medicine as a real-world exposure source.
- name: Deliberate beverage contamination
  description: >-
    Criminal poisoning by thallium-adulterated food or beverages remains an
    important forensic exposure context.
  exposure_term:
    preferred_term: exposure to thallium
    term:
      id: ECTO:9001312
      label: exposure to thallium
    qualifiers:
    - predicate:
        preferred_term: has input
        term:
          id: RO:0002233
          label: has input
      value:
        preferred_term: thallium molecular entity
        term:
          id: CHEBI:37110
          label: thallium molecular entity
    - predicate:
        preferred_term: has participant
        term:
          id: RO:0000057
          label: has participant
      value:
        preferred_term: digestive system
        term:
          id: UBERON:0001007
          label: digestive system
  evidence:
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Following this investigation, a criminal suspect confessed to two instances of adulterating thallium sulfate in the patient's beverage."
    explanation: Supports deliberate beverage adulteration as a documented exposure scenario.
diagnosis:
- name: Blood and urine thallium measurement
  description: >-
    Direct measurement of blood and urine thallium concentration is the core
    laboratory method for confirming suspected poisoning.
  diagnosis_term:
    preferred_term: blood chemistry measurement
    term:
      id: MAXO:0000787
      label: blood chemistry measurement
  markers: Blood thallium concentration and urinary thallium concentration
  results: Elevated blood and/or urinary thallium levels confirm exposure.
  evidence:
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The correct diagnosis was confirmed by blood and urine thallium assays."
    explanation: Directly supports blood and urine thallium assays as confirmatory testing.
- name: Clinical recognition of the gastrointestinal-neurologic-cutaneous triad
  description: >-
    Concurrent gastrointestinal symptoms, progressive neurologic abnormalities,
    and cutaneous changes such as alopecia should raise suspicion for thallium
    poisoning.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thallium intoxication may have been initially identified if neurologic symptoms had occurred concurrently with gastrointestinal and cutaneous symptoms."
    explanation: Supports symptom-pattern recognition as an important clinical diagnostic clue.
- name: Hair thallium analysis
  description: >-
    Hair thallium concentration can support diagnosis when exposure occurred
    weeks earlier or when alopecia has become prominent.
  diagnosis_term:
    preferred_term: clinical laboratory procedure
    term:
      id: MAXO:0000006
      label: clinical laboratory procedure
  markers: Thallium concentration in hair
  results: Increased hair thallium concentration supports prior exposure.
  evidence:
  - reference: PMID:28761262
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The increased concentration of thallium in the hair helps in the diagnosis of this poisoning."
    explanation: Supports hair analysis as a useful diagnostic matrix in thallium toxicology.
- name: Supportive neurophysiology in suspected toxic neuropathy
  description: >-
    Nerve conduction studies can support the diagnosis by documenting a toxic
    peripheral sensorimotor neuropathy pattern.
  diagnosis_term:
    preferred_term: diagnostic procedure of nervous system
    term:
      id: MAXO:0001406
      label: diagnostic procedure of nervous system
  evidence:
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nerve conduction studies demonstrated features of peripheral sensorimotor neuropathy"
    explanation: Supports electrophysiology as a useful supportive test in thallium-associated neuropathy.
differential_diagnoses:
- name: Arsenic Poisoning
  distinguishing_features:
  - Thallium poisoning is more strongly associated with dramatic delayed alopecia
  - Thallium typically causes extremely painful ascending sensory neuropathy
  - Arsenic more often causes hyperpigmentation and palmoplantar keratoses in chronic exposure
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The major manifestations of toxicity consist of a rapidly progressive, ascending, extremely painful sensory neuropathy and alopecia."
    explanation: Supports the thallium-specific combination of painful ascending neuropathy and alopecia that helps distinguish it from arsenic poisoning.
- name: Lead Poisoning
  distinguishing_features:
  - Lead poisoning more often produces anemia, basophilic stippling, and chronic cognitive effects
  - Thallium poisoning is more strongly linked to alopecia and painful sensory neuropathy
  evidence:
  - reference: PMID:6338655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In humans the most characteristic sign of thallium toxicity is alopecia which usually appears in cases when death is delayed for 15-20 days."
    explanation: Supports alopecia as a strong distinguishing clue favoring thallium poisoning over lead poisoning.
- name: Guillain-Barre Syndrome
  distinguishing_features:
  - Thallium poisoning is suggested by gastrointestinal prodrome and delayed alopecia
  - Laboratory thallium assays confirm toxic exposure rather than postinfectious neuropathy
  evidence:
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A 43-year-old man was initially misdiagnosed as gastroenteritis, diabetic peripheral neuropathy, and Guillain-Barré Syndrome (GBS) within 21 months."
    explanation: Supports Guillain-Barre syndrome as a common clinical mimic in misdiagnosed thallium poisoning.
treatments:
- name: Exposure cessation and source removal
  description: >-
    Management begins with immediate cessation of exposure and removal of the
    toxic source to prevent ongoing absorption.
  treatment_term:
    preferred_term: chemical exposure avoidance
    term:
      id: MAXO:0000071
      label: chemical exposure avoidance
    qualifiers:
    - predicate:
        preferred_term: has input
        term:
          id: RO:0002233
          label: has input
      value:
        preferred_term: thallium molecular entity
        term:
          id: CHEBI:37110
          label: thallium molecular entity
  target_mechanisms:
  - target: Gastrointestinal absorption of thallium
    treatment_effect: INHIBITS
    description: Source control prevents continued ingestion and limits additional thallium uptake.
    evidence:
    - reference: PMID:14579545
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Thallium salts are rapidly and nearly completely absorbed by virtually all routes, with gastrointestinal exposure being the most common route to produce toxicity."
      explanation: Supports exposure cessation as an intervention that limits further gastrointestinal absorption of thallium.
  evidence:
  - reference: PMID:36537175
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "An adequate clinical approach can facilitate early diagnosis."
    explanation: Supports the clinical importance of early recognition, which is necessary for prompt removal from exposure and source control.
- name: Prussian blue therapy
  description: >-
    Prussian blue is the preferred antidotal therapy for acute thallium
    poisoning because it enhances gastrointestinal elimination and has the best
    available safety profile among proposed drug therapies.
  treatment_term:
    preferred_term: antidote agent therapy
    term:
      id: MAXO:0000217
      label: antidote agent therapy
    qualifiers:
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: Prussian blue
        term:
          id: CHEBI:30069
          label: ferric ferrocyanide
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Prussian blue's safety profile is superior to that of other proposed therapies and it should be considered the drug of choice in acute thallium poisoning."
    explanation: Directly supports Prussian blue as the preferred antidotal treatment in acute poisoning.
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "After Prussian blue treatment, thallium was undetectable in the blood by day 60."
    explanation: Human case evidence supports effective thallium clearance during Prussian blue treatment.
- name: Multiple-dose activated charcoal
  description: >-
    Single- or multiple-dose activated charcoal can be used to reduce ongoing
    gastrointestinal absorption and interrupt enteroenteric or enterohepatic
    recycling.
  treatment_term:
    preferred_term: supportive care
    term:
      id: MAXO:0000950
      label: supportive care
    qualifiers:
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: charcoal
        term:
          id: CHEBI:91090
          label: charcoal
  evidence:
  - reference: PMID:14579545
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The use of single- or multiple-dose activated charcoal is supported by in vitro binding experiments and some animal data"
    explanation: Supports activated charcoal as an adjunctive decontamination strategy, though the evidence base is indirect.
- name: Potassium supplementation
  description: >-
    Potassium supplementation has historically been used to enhance thallium
    elimination and remains part of classic treatment regimens.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    qualifiers:
    - predicate:
        preferred_term: therapeutic agent
        term:
          id: NCIT:C2259
          label: Therapeutic Agent
      value:
        preferred_term: potassium chloride
        term:
          id: CHEBI:32588
          label: potassium chloride
  evidence:
  - reference: PMID:6338655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The current therapy for thallium poisoning is the use of prussian blue and potassium chloride."
    explanation: Supports potassium chloride as part of established treatment regimens for thallium poisoning.
  - reference: PMID:6338655
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Potassium therapy is probably the single most effective agent in the treatment of thallium poisoning."
    explanation: Supports historical therapeutic use of potassium therapy to enhance elimination.
- name: Extracorporeal elimination adjuncts
  description: >-
    Hemoperfusion or hemodialysis may be used as adjunctive therapy in severe
    poisoning, especially when neurologic toxicity is advanced or ongoing
    elimination support is needed.
  treatment_term:
    preferred_term: hemodialysis
    term:
      id: MAXO:0000602
      label: hemodialysis
  evidence:
  - reference: PMID:14579545
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "charcoal haemoperfusion may be a useful adjunct."
    explanation: Supports extracorporeal elimination as an adjunctive rather than definitive therapy.
epidemiology:
- name: Rare and often misdiagnosed poisoning
  description: >-
    Thallium poisoning is uncommon, and delayed recognition remains a major
    epidemiologic and clinical problem because the early syndrome is nonspecific.
  evidence:
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thallium poisoning is a rare occurrence. Therefore, thallium poisoning is easily misdiagnosed"
    explanation: Supports rarity and frequent misdiagnosis as defining epidemiologic features.
- name: Sparse published multi-case burden with prolonged diagnostic delay
  description: >-
    The published multisubject thallium poisoning literature remains small, and
    the interval from symptom onset to diagnosis can range from hours to years.
  evidence:
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nine articles including 98 cases with thallium poisoning were retrieved in our literature review"
    explanation: Supports that the modern human thallium poisoning literature includes relatively few reported multi-case series.
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the durations from symptom onset to diagnosis ranged from several hours to four years, even after autopsy"
    explanation: Supports major diagnostic delay as an important epidemiologic feature of reported thallium poisoning.
- name: Accidental and criminal exposure patterns
  description: >-
    Reported cases arise from both accidental exposure and intentional
    poisoning, including contaminated medicines and homicide attempts.
  evidence:
  - reference: PMID:28761262
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thallium is a toxic heavy metal often involved in criminal poisonings and occasionally in accidental poisoning."
    explanation: Supports both criminal and accidental exposure patterns in human cases.
prevalence:
- population: Published multi-case human thallium poisoning literature through September 2020
  notes: >-
    A literature review identified nine publications comprising 98 reported
    cases. This supports clinical rarity, but does not provide a stable
    denominator-based population prevalence estimate.
  evidence:
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Nine articles including 98 cases with thallium poisoning were retrieved in our literature review"
    explanation: Provides a concrete published case count showing that reported multi-case thallium poisoning literature remains sparse.
  - reference: PMID:33438838
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thallium poisoning is a rare occurrence."
    explanation: Supports rarity of thallium poisoning, while also indicating the absence of a robust population prevalence estimate in the current source set.
histopathology:
- name: Diffuse alveolar damage and pulmonary edema in fatal acute poisoning
  description: >-
    Fatal acute thallium poisoning can show severe pulmonary edema, pulmonary
    hemorrhage, and hyaline membrane formation, providing the histopathologic
    correlate of acute respiratory distress syndrome.
  context: Autopsy findings in fatal acute thallium poisoning
  diagnostic: false
  evidence:
  - reference: PMID:40884943
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "large amounts of pleural effusion, severe pulmonary edema, pulmonary hemorrhage, and hyaline membrane formation in the lung tissue suggested acute respiratory distress syndrome (ARDS)."
    explanation: Supports diffuse acute lung injury with hyaline membrane formation as a histopathologic pattern in severe fatal thallium poisoning.
datasets:
- accession: geo:GSE213589
  title: Transcriptomic alterations of thallium-exposed zebrafish embryos
  description: >-
    Bulk RNA-seq toxicogenomic dataset profiling wild-type zebrafish embryos
    exposed to graded thallium concentrations during early development, useful
    for studying developmental and stress-response programs perturbed by
    thallium.
  organism:
    preferred_term: zebrafish
    term:
      id: NCBITaxon:7955
      label: Danio rerio
  data_type: BULK_RNA_SEQ
  sample_count: 10
  conditions:
  - wild-type zebrafish embryos exposed to 0 ppb thallium
  - wild-type zebrafish embryos exposed to 200 ppb thallium
  - wild-type zebrafish embryos exposed to 800 ppb thallium
  exposures:
  - preferred_term: exposure to thallium
    term:
      id: ECTO:9001312
      label: exposure to thallium
  publication: PMID:36403832
  evidence:
  - reference: GEO:GSE213589
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Thallium (Tl) is a trace metal element used in the electronics, semiconductor and electro-optical industries. With the development of high-tech industries, thallium severely pollutes the aquatic environment. The purpose of this study was to evaluate the cardiotoxicity and developmental toxicity of Tl by using vertebrate model zebrafish embryos. RNA-seq was performed on wild type zebrafish embryos exposed to 0, 200, and 800 ppb Tl from 6 to 48 hpf. The transcriptomic profile revealed molecular understanding regarding the cardiovascular and developmental toxicity of Tl, providing valuable information for risk assessment of the emerging contaminant thallium."
    explanation: Supports this GEO series as a model-organism bulk RNA-seq resource directly profiling transcriptomic responses to graded thallium exposure.
  notes: >-
    Dataset record: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE213589.
    Useful as a mechanistic toxicogenomic resource rather than a human clinical
    cohort.
- accession: geo:GSE269635
  title: Dissociation of mitochondrial and ribosomal biogenesis during thallium administration in rat kidney
  description: >-
    Rat kidney microarray dataset profiling early transcriptomic responses after
    short-course thallium administration, useful for studying renal
    bioenergetic and stress-response pathways in thallium toxicity.
  organism:
    preferred_term: rat
    term:
      id: NCBITaxon:10116
      label: Rattus norvegicus
  data_type: MICROARRAY
  sample_count: 3
  conditions:
  - rat kidney control
  - rat kidney after 2 days of thallium administration
  - rat kidney after 5 days of thallium administration
  exposures:
  - preferred_term: exposure to thallium
    term:
      id: ECTO:9001312
      label: exposure to thallium
  platform: ClariomS
  evidence:
  - reference: GEO:GSE269635
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We analyzed kidney from rats administered thallium (30 mg/kg, daily for 2 or 5 days) using the ClariomS platform."
    explanation: Supports this GEO series as a rat kidney microarray resource for short-course experimental thallium toxicity.
  notes: >-
    Dataset record: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE269635.
    Useful as a mechanistic renal toxicogenomic resource rather than a human
    clinical cohort.
references:
- reference: PMID:6338655
  title: "Thallium poisoning: a review."
  findings: []
- reference: PMID:14579545
  title: "Thallium toxicity and the role of Prussian blue in therapy."
  findings: []
- reference: PMID:15252192
  title: "Soluble or insoluble prussian blue for radiocesium and thallium poisoning?"
  findings: []
- reference: PMID:33438838
  title: "Long-term misdiagnosis and neurologic outcomes of thallium poisoning: A case report and literature review."
  findings: []
- reference: PMID:36537175
  title: "Thallium poisoning: a case report."
  findings: []
- reference: PMID:28761262
  title: "Acute Alopecia: Evidence to Thallium Poisoning."
  findings: []
- reference: PMID:31335706
  title: "Clinical characteristics and treatment of thallium poisoning in patients with delayed admission in China."
  findings: []
- reference: PMID:11192464
  title: "Thallium poisoning during pregnancy: a case report and comprehensive literature review."
  findings: []
- reference: PMID:40884943
  title: "Acute thallium poisoning: An autopsy case report and review of the literature."
  findings: []
- reference: PMID:36403832
  title: "Integrated physiological, biochemical, and transcriptomic analysis of thallium toxicity in zebrafish (Danio rerio) larvae."
  findings: []